Advertisement

Topics

Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights

08:30 EST 9 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
AURA-LV Phase IIb Study Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study 48-Week AURA-LV Data to be presented in Late Breaker Presentation at National Kidn...

Other Sources for this Article

Aurinia Pharmaceuticals Inc.
Investor & Media:
Celia Economides
Head of IR & Communications
ceconomides@auriniapharma.com
or
Chief Financial Officer:
Dennis Bourgeault, 780-643-2260
780-484-4105 (fax)
dbourgeault@auriniapharma.com

NEXT ARTICLE

More From BioPortfolio on "Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Lupus
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...